Cordlife proposes to merge with NY-listed life sciences enterprise
Add BT as a preferred sourceSingapore
CORDLIFE Group on Tuesday said that it has made an indicative, non-binding and conditional proposal to merge with New York-listed Global Cord Blood Corporation.
Global Cord Blood Corporation provides cord blood collection, laboratory testing, haematopoietic stem cell processing and stem cell storage services in China. It is incorporated in the Cayman Islands and listed on the New York Stock Exchange (NYSE).
TRENDING NOW
Eligible Singaporeans to receive up to S$850 in GSTV cash, up to S$450 in MediSave top-ups in August
Supermarket and minimart chain Hao Mart faces fifth High Court lawsuit
DBS, OCBC, UOB push STI to new highs as institutions pile in ahead of earnings
With AI, it’s not about coding better; workers need to think better: Koh Boon Hwee
